Saroglitazar is a dual regulator that corrects both the lipid profile and the glycemic indices. It is a potent and predominantly Peroxisome Proliferator Activated Receptor (PPAR)-alpha agonist with moderate PPAR-gamma agonistic activity. PPARs are nuclear lipid-activated transcription factors that regulate the expression of various genes involved in the control of lipid and lipoprotein metabolism, glucose homeostasis and inflammatory processes. It decreases the post prandial rise of plasma free fatty acids, improves post-absorptive insulin-mediated suppression of hepatic glucose output, reduces the metabolic burden on liver & muscle and promotes glucose utilization.
For diabetic dyslipidemia and hypertriglyceridemia with Type 2 diabetes mellitus not controlled by statin therapy. It has also shown favorable glycemic indices by reducing the fasting plasma glucose and glycosylated hemoglobin in diabetic patients.
oral; 4mg once a day.
Hypersensitivity to saroglitazar.
Paediatric: Safety and efficacy of saroglitazar in pediatric patients have not been established.
Pregnancy: Category C; It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: it is not known whether Saroglitazar is excreted into the breast milk.
Elderly: It should be used with caution in geriatric patients.
gastritis, asthenia and pyrexia.
Data not sufficient.